BPI leads €13m series-A for NH TherAguix

BPI's investment comes from its InnoBio 2 fund, which has a target of €250m. The fund was launched in 2018 and BPI France is a cornerstone investor for the fund with a 49% stake. Supernova's investment came from its Supernova 2 fund, which held its final close on €75m in 2017.

Omnes and investment management firm Arbevel are new investors.

Previous funding
In 2016, Insavalor, Ezus, Avnir, Nano-H, Chematech and some private individuals invested €597,000 to produce NH TherAguix's drug and design its first phase-II trial.

NH TherAguix realised a capital increase of €1.1m from the Pre-IPO Invest Securities platform in 2017.

In July 2018, NH TherAguix raised €1.1m from business angels and Supernova Invest.

Company
Founded in 2015 and headquartered in Lyon Saint-Etienne. NH TherAguix combines three essential attributes to fight tumours: targeting, imaging and treatment. Its drug candidate AGuIX is in the trial phase. The company employs eight people.

People
BPI France – Philippe Boucheron (deputy director of life sciences investment).
Omnes Capital – Maximilien Fournier-Sourdille (principal).
Arbevel – Marc Le Bozec (fund manager).
Supernova Invest – Celia Hart (partner).
NH TherAguix – Géraldine Le Duc (co-founder, CEO); Olivier Tillement (co-founder, chief science officer).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• France
• Healthcare
• healthcare
• Omnes Capital
• BPI France
• France